T2 Biosystems (NASDAQ:TTOO – Get Free Report) issued its quarterly earnings data on Monday. The medical equipment provider reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.31, Yahoo Finance reports. The firm had revenue of $1.95 million during the quarter. T2 Biosystems updated its FY 2024 guidance to EPS.
T2 Biosystems Price Performance
Shares of TTOO stock opened at $5.10 on Tuesday. The firm has a 50 day moving average of $5.12 and a two-hundred day moving average of $4.47. T2 Biosystems has a 52 week low of $2.60 and a 52 week high of $70.00.
Analyst Ratings Changes
Separately, Canaccord Genuity Group boosted their price target on shares of T2 Biosystems from $3.00 to $5.00 and gave the stock a “hold” rating in a research note on Tuesday.
About T2 Biosystems
T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.
Featured Articles
- Five stocks we like better than T2 Biosystems
- Basic Materials Stocks Investing
- Has Micron’s Stock Drop Turned Into A Screaming Buy?
- Stock Analyst Ratings and Canadian Analyst Ratings
- Should You Invest in Bonds? Here’s What to Know
- What Are Dividend Champions? How to Invest in the Champions
- Why This Manufacturer is Committing to a Massive Buyback Program
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.
